A case of heterogeneous breast cancer with clonally expanded T-cells in the HER2+ and metastasis of the HER2- tumor cells

Breast Journal

Volumn 14, Issue 5, 2008, Pages 487-491

  Wiech, Thorsten ^a   Nikolopoulos, Elisabeth ^a   Hausmann, Michael ^a,b   Walch, Axel ^a,c   Werner, Martin ^a   Fisch, Paul ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Array CGH; Breast carcinoma; HER2 amplification; T cell clonality; Tumor infiltrating lymphocytes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER IMMUNOLOGY; CASE REPORT; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; T LYMPHOCYTE;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RISK ASSESSMENT;

EID: 51349137559     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00627.x     Document Type: Article

References (14)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 : 783 92.
2. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001 93 : 1141 6.
3. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005 93 : 552 6.
4. Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997 3 : 817 9.
5. Whitford P, Mallon EA, George WD, et al. Flow cytometric analysis of tumor infiltrating lymphocytes in breast cancer. Br J Cancer 1990 62 : 971 5.
6. Albrecht B, Hausmann M, Zitzelsberger H, et al. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 2004 203 : 780 8.
7. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003 17 : 2257 317.
8. Tang RP, Kacinski B, Validire P, et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem 1990 44 : 189 98.
9. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007 117 : 1137 46.
10. Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumor vaccines for T cell recognition. Breast Cancer Res 2001 3 : 399 403.
11. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994 54 : 16 20.
12. Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995 92 : 432 6.
13. Fritz P, Cabrera CM, Dippon J, et al. c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res 2005 7 : R374 84.
14. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 : 707 12.